Condition: Myelofibrosis · Sponsor: Geron Corporation
The purpose of the study is to identify the recommended Part 2 dose (R2PD) of imetelstat sodium in combination with ruxolitinib in participants with myelofibrosis (MF) in Part 1, and to evaluate the safety and preliminary clinical activity of the R2PD of imetelstat sodium in combination with ruxolitinib in participants with MF in Part 2.
This description comes directly from the study's public registry record.
Michelle Mudge-Riley, DO · 650-473-7793 · myf1001-info@geron.com
Judy Ho · 650-473-7793 · myf1001-info@geron.com
Always discuss trial participation with your own doctor first.
| City of Hope | Duarte, California, United States | Recruiting |
| City of Hope | Irvine, California, United States | Recruiting |
| University of Miami | Coral Gables, Florida, United States | Recruiting |
| H. Lee Moffitt Cancer Center and Research Institute, Inc. | Tampa, Florida, United States | Recruiting |
| Icahn School of Medicine at Mount Sinai | New York, New York, United States | Recruiting |
| Texas Oncology | Denison, Texas, United States | Withdrawn |
| Texas Oncology | Tyler, Texas, United States | Withdrawn |
| Fred Hutchinson Cancer Center | Seattle, Washington, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05371964